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Epstein–Barr virus (EBV) was the first human virus proved to be closely associated 
with tumor development, such as lymphoma, nasopharyngeal carcinoma, and EBV-
associated gastric carcinoma. Despite many efforts to develop prophylactic vaccines 
against EBV infection and diseases, no candidates have succeeded in effectively block-
ing EBV infection in clinical trials. Previous investigations showed that EBV gp350 plays 
a pivotal role in the infection of B-lymphocytes. Nevertheless, using monomeric gp350 
proteins as antigens has not been effective in preventing infection. Multimeric forms of 
the antigen are more potently immunogenic than monomers; however, the multimeriza-
tion elements used in previous constructs are not approved for human clinical trials. 
To prepare a much-needed EBV prophylactic vaccine that is potent, safe, and appli cable, 
we constructed an Fc-based form of gp350 to serve as a dimeric antigen. Here, we 
show that the Fc-based gp350 antigen exhibits dramatically enhanced immunogenicity 
compared with wild-type gp350 protein. The complete or partial gp350 ectodomain was 
fused with the mouse IgG2a Fc domain. Fusion with the Fc domain did not impair gp350 
folding, binding to a conformation-dependent neutralizing antibody (nAb) and binding to 
its receptor by enzyme-linked immunosorbent assay and surface plasmon resonance. 
Specific antibody titers against gp350 were notably enhanced by immunization with 
gp350-Fc dimers compared with gp350 monomers. Furthermore, immunization with 
gp350-Fc fusion proteins elicited potent nAbs against EBV. Our data strongly suggest 
that an EBV gp350 vaccine based on Fc fusion proteins may be an efficient candidate to 
prevent EBV infection in clinical applications.
Keywords: epstein–Barr virus, envelope protein, gp350, Fc-based vaccine, neutralizing antibody, intranasal 
immunization
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inTrODUcTiOn
Epstein–Barr virus (EBV), known as human herpesvirus 4, is a 
highly prevalent virus from the Herpesviridae γ subfamily (1). 
EBV is the first virus reported to cause tumorigenesis in infected 
humans (1–3). It is widely spread among human populations, 
and over 95% of adults carry latent EBV worldwide (4, 5). EBV 
establishes lifelong latency in infected individuals. Three types 
of  latencies have been described based on the subset of genes 
expressed in latently infected cells (6). The latent status of EBV 
is closely linked to the development and progression of many 
diseases, such as infectious mononucleosis (IM), nasopharyngeal 
carcinoma (NPC), posttransplant lymphoproliferative disease, 
EBV-related gastric carcinoma, and Hodgkin lymphoma (7–14). 
In some southern provinces of China, where NPC is frequent, 
it has the highest fatality rate among malignancies. Thus, EBV-
associated diseases are an important public health concern. 
In addition, latent EBV infection was recently shown to accelerate 
the decay of childhood measles and rubella vaccine responses (15). 
However, at present no EBV vaccine is available. Development of 
a successful EBV vaccine is difficult due to (i) the lack of appro-
priate animal models for evaluation of infection, (ii)  the poor 
protection of previous vaccine candidates, and (iii)  inadequate 
investment in vaccine development (16–18).
To initiate EBV infection, several viral envelope glycoproteins 
are involved in entry into target cells such as epithelial cells or 
B-lymphocytes (19, 20). Out of these glycoproteins, gp350 is gen-
erally considered to be involved in the infection of B-lymphocytes 
(21). Two cellular receptors, CR2/CD21 and CD35, bind gp350 
during entry. The crystal structure of gp350 ectodomain (residues 
1–470) showed that about 14 large glycan chains cover the whole 
surface of gp350 except for the area, which is responsible for bind-
ing to CR2/CD21 (22). Despite being the most abundant EBV 
glycoprotein on virions (23), this glycosylation pattern suggests 
that native gp350 remains monomeric since its important glycan 
coverage may prevent protein-protein interaction on the viral 
envelope (22). Importantly, a monoclonal antibody (mAb72A1), 
which was raised against gp350, effectively blocks EBV infection 
of B cells (24–27). Hence, gp350 has been the primary antigen used 
in the development of EBV prophylactic vaccines (17). Initially, 
Epstein et al. reported that using purified gp350 as antigen can pro-
tect cotton marmosets from developing lymphoma caused by EBV 
infection (28). In some cases, the immune sera could block infec-
tion although neutralizing antibodies (nAbs) were rarely found. 
This observation implied that most antibodies against purified 
gp350 probably clear the virus through ADCC or T cell responses 
(29–31). Polymerization of gp350 on the surface of ferritin nano-
particles significantly increased antigenicity and protected mice 
against infection by a recombinant vaccinia virus expressing EBV 
gp350 (32). Candidate vaccines based on gp350 have been tested 
in clinical trials. Recombinant vaccinia vectors expressing gp350 
elicited nAbs against EBV (33). More recently, a recombinant 
gp350 antigen induced protection from EBV infection in a Phase 
I/II clinical trial (34). Despite these results, none of these trials have 
yet reached the final stage of vaccine development. Interestingly, 
in a Phase II trial performed with seronegative individuals, IM 
incidence was notably decreased, but EBV infection could not be 
blocked (35). Besides, recombinant gp350 did not induce nAbs 
in a cohort of children awaiting kidney transplants, even though 
the specific antibody titer increased soon after immunization (36).
In Fc-based fusion antigens, the Fc domain of immunoglobu-
lins is fused with the desired protein, which allows the dimeri-
zation of the protein and often potently increases its biological 
and pharmacological characteristics (37–39). The fusion with 
the Fc domain can remarkably increase plasma half-life and 
immunogenicity of recombinant antigens. This appears to be due 
to the combination of a high affinity for the neonatal Fc receptor 
(FcRn) and a slower clearance due to higher molecular weight 
(40–42). Besides, the Fc fusion proteins can be easily purified 
through protein A/G affinity chromatography. Furthermore, the 
safety of use of Fc in fusion proteins in humans has been clearly 
established during the development of Fc-based protein drugs 
and therapeutic mAbs (37, 43). For all these reasons, we believe 
that an Fc fusion approach is a valid way to improve EBV g350 
antigen immunogenicity and efficacy as a prophylactic vaccine.
In this study, we expressed two forms of recombinant EBV 
gp350 ectodomain fused with the Fc domain of mouse IgG2a 
(mIgG2a-Fc) in insect cells. We used the N-terminal three 
domains of gp350 (gp350-ECD123) or the full-length gp350 
ectodomain (gp350-ECDFL). We found that the fusion with Fc 
did not affect the neutralizing epitope recognized by mAb72A1 
or the CR2/CD21 binding site of gp350. The immunogenicity of 
gp350-ECD123 and gp350-ECDFL with and without Fc fusion was 
compared in BALB/c mice. Infection neutralization assays and 
antibody-dependent competition indicated that recombinant 
gp350 fused with Fc domain elicited more potent nAbs compared 
with non-fusion monomeric gp350 proteins.
MaTerials anD MeThODs
construction of recombinant Bacmids 
With insertion of gp350 ectodomain 
Fused With migg2a-Fc
Two variants of EBV gp350 ectodomain, gp350-ECD123 (residues 
1–425, corresponding to the first three N-terminal domains) and 
gp350-ECDFL (residues 1–803, corresponding to the full-length 
ectodomain) were used. The corresponding sequences from 
strain M81 were obtained by PCR amplification using specific 
primers: gp350-ECD123-BamH I-F (5′-CGCGGATCCGCCAC 
CATGGTAAGCGCTATTGTTTTATATGTGCTTTTGGCGG 
CGGCGGCGCAT TCTGCCT T TGCGATGGAGGCAG 
CCTTGCTTGTG-3′) and gp350-ECD123-Sal I-R (5′-ACGCGTC 
GAC GGGTGCCTTGGAGAATATAACCTTGTG-3′) for gp350- 
ECD123, gp350-ECDFL-BamH I-F (5′-CGC GGATCCGCCACC 
ATGGTAAGCGCTATTGTTTTATATGTGCTTTTGGCG 
GCGGCGGCGCAT TCTGCCT T TGCGATGGAGGCA 
GCCTTGCTTGT-3′) and gp350-ECDFL-Sal I-R (5′-ACGCGT 
CGAC GGAGAGGTTTGAGAATCTGG-3′) for gp350-ECDFL. 
These two fragments were inserted into the pFastBac1 vector 
(Invitrogen) by BamH I/Sal I digestion. To guide the secretion 
of the Fc fusion proteins and obtain correct glycosylation, the 
coding sequence of gp64 signal peptide was added at the 5′ end 
of the gp350 fragment by inclusion in the primers. The coding 
FigUre 1 | Continued
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fragment of mIgG2a-Fc was synthesized as previously reported 
(44) and added to the 3′ end of the gp350 fragments by Sal I/Xba 
I digestion. The soluble gp350-ECD123 was constructed by adding 
a C-terminal hexa-histidine tag, and an N-terminal gp64 signal 
peptide fragment included in the PCR primers. The resulting 
constructs are shown in Figure 1A.
FigUre 1 | Characterization of Fc-based recombinant gp350 proteins. (a) Diagrams for design of Fc-based recombinant gp350 proteins. The extracellular domains 
(D-I, D-II, and D-III), transmembrane domains, and cytoplasmic tail (TD/CT) are shown in gray. The 6-histidine tag is shown as a hatched box, the mouse IgG2a Fc 
domain is shown orange, and the glycine–serine (G4S)3 linker is colored green. (B) Western blot of secreted recombinant gp350 constructs under reducing (+β-ME) 
and non-reducing conditions (−β-ME). gp350-ECD123-6His was detected by an anti-His tag antibody, and proteins fused with Fc domain were detected with an 
anti-mouse Fc antibody. For each fusion protein, the same volume (15 µl) of supernatants from identical passage 1 baculovirus stocks was loaded onto the gels 
under reducing and non-reducing conditions. Samples were resolved on 10% SDS-PAGE. (c) Detection of the indicated recombinant gp350 forms by 
conformation-dependent anti-gp350 mAb72A1 antibody in the supernatant of bacmid-transfected Sf9 cells using dot blot. Cell culture supernatants from 
mock-transfected cells were included as negative controls. (D) SDS-PAGE analysis of SEC-purified forms of recombinant gp350. Proteins from the peak  
fractions were resolved on 10% gel under reducing condition and stained with Coomassie brilliant blue.
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The recombinant bacmids containing the coding fragments 
of mIgG2a-Fc fusion protein were constructed according to the 
manufacturer’s manual. Briefly, DH10B cells were transformed by 
heat shock with each plasmid constructs. The DH10B cells with 
positive recombinant bacmids were isolated as white colonies on 
LB agar plates containing kanamycin, gentamicin, tetracycline, 
Bluo-gal, and IPTG. Positive colonies were validated by restreak-
ing and the presence of genes encoding fusion proteins was 
verified by PCR using pUC/M13 Forward and Reverse primers. 
Finally, the recombinant bacmids were extracted by alkaline 
lysis, dissolved in TE buffer, and stored at −20°C for subsequent 
transfection.
expression and Purification of Fc Fusion 
Proteins
The expression of Fc fusion proteins in insect cells followed the 
bac-to-bac manual of Invitrogen. Briefly, ~8 × 105 Sf9 cells per 
well were seeded in a 6-well plate and cultured in monolayers in 
Sf900-III media (Invitrogen) and transfected with recombinant 
bacmids using Cellfectin reagents (Invitrogen). Expression was 
validated in passage 1 (P1) baculovirus stocks after 7–10  days 
by Western blot. The P1 baculoviruses were subjected to two 
rounds of plaque selection to obtain positive pure recombinant 
viruses. For protein expression, P1 recombinant viruses were 
subjected to two cycles of amplification in High 5 cells cultured in 
suspension in ESF921 medium (Expression system). High 5 cells 
were seeded at 0.5 × 106 cells/ml and infected with recombinant 
viruses when the cell density reached 1.5–2.0 × 106 cells/ml. The 
multiplicity of infection and infection time were optimized for 
each recombinant fusion protein to maximize protein expression 
levels. Culture supernatants containing recombinant proteins 
were harvested 4–5  days posttransfection, and cell debris was 
removed by centrifugation and 0.45 µm filtration.
All culture supernatants were concentrated 10-fold using Mini 
Pellicon TFF system (Millipore). Soluble gp350-ECD123-6His was 
purified using HisTrap FF prepacked column (GE Healthcare) 
with a GE Akta purifier chromatography system. The concen-
trated supernatants were dialyzed against equilibration buffer 
(20 mM Tris–HCl, 300 mM NaCl, 10 mM imidazole, pH 7.5), and 
the HisTrap column was equilibrated with 5–10 column volumes 
of equilibration buffer. The dialyzed supernatants were applied 
on the column, which was washed with equilibration buffer until 
the absorbance reached baseline. Elution was performed using 
at least five column volumes of elution buffer (20 mM Tris–HCl, 
300 mM NaCl, 60 mM imidazole, pH 7.5). For purification of Fc 
fusion proteins, the concentrated supernatants were loaded on 
the pre-equilibrated HiTrap Mabselect column (GE Healthcare) 
after dialyzed against 1× PBS. The bound fusion proteins were 
eluted using 100 mM sodium citrate, pH 3.0, and neutralized with 
1 M Tris–HCl, pH 9.5 (300 µl Tris–HCl buffer per 1 ml elution). 
All the eluted proteins were subjected to SDS-PAGE and 
Coomassie staining for purity check.
The purified proteins were immediately dialyzed against 1× 
PBS and loaded on a Superdex200 increase 10/300 GL prepacked 
column (GE Healthcare) for further purification. Generally, 
the samples were concentrated four to five times for loading, 
and the flow rate was set to 0.5 ml/min. The protein absorbance 
was monitored at 280  nm. The eluted fractions were checked 
for purity of fusion proteins using SDS-PAGE, pooled together, 
and protein concentration was determined using BCA assay kit 
(Thermo Scientific Pierce) after concentration. Finally, the fusion 
proteins were aliquoted and stored at −80°C.
construction and Purification of human 
cr2 (scr1-2) Fused With MBP Tag
The construction and purification of human CR2 (SCR1-2) fusion 
protein was performed as described previously (45). Briefly, 
coding sequence corresponding to residues 1–133 of wild-type 
human CR2 (SCR1-2) was synthesized and inserted into pMAL-
p5x (New England BioLabs) by digestion and ligation steps. The 
positive plasmid was introduced into BL21 bacteria for protein 
expression. Crude bacterial lysates were filtered and loaded on the 
MBPTrap HP column (GE Healthcare). The fusion proteins were 
eluted using 10 mM maltose in equilibration buffer. Finally, MBP-
hCR2 SCR1-2 proteins were purified further using size exclusion 
chromatography described earlier after dialyzed against 1× PBS 
and aliquoted to store at −80°C.
sDs-Page and immunoblot
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) was performed on 10 or 4–12% gradient acrylamide 
gels. Generally, gels were ran for 1  h at 160  V. Total proteins 
were visualized by Coomassie brilliant blue staining for 1 h and 
destained until the background became transparent.
For immunoblotting, after SDS-PAGE, proteins were trans-
ferred onto polyvinylidene fluoride membrane (Millipore) for 2 h 
30 min at 300 mA. Membranes were blocked in 5% non-fat milk 
(dissolved in TBST buffer containing 25 mM Tris, 250 mM NaCl, 
0.1% Tween-20, pH 7.4) for at least 2  h at room temperature. 
For  detection of soluble gp350-ECD123-6His, primary mouse 
anti-His antibody (Abmart) was diluted 1:2,000 and incubated 
with membrane at 4°C overnight following incubation with sec-
ondary goat anti-mouse antibody (1:20,000, Promega) conjugated 
to horseradish peroxidase (HRP) for 1 h at room temperature. 
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For detection of Fc fusion proteins, the membranes were incubated 
directly with secondary goat anti-mouse antibody (1:20,000) for 
detection using ECL substrate (Advansta).
Mouse immunization
Five BALB/c female mice (6–8 weeks old) for each group were 
immunized with antigens intraperitoneally (i.p.) or intranasally 
(i.n.). For i.p. immunization, fusion proteins were adsorbed to 
Imject Alum adjuvant (Invitrogen) according to the  manufacturer’s 
instructions, and two doses were tested, 1 or 20  µg. Primary 
immunization was performed after collection of preimmune sera 
at week 0 and followed by one boost at week 3. For i.n. immuniza-
tion, 20 µg antigens (per mouse) was mixed with 25 µg CpG1826 
(InvivoGen) and dissolved in 1× PBS, and the final volume was 
brought to 30 µl. Mice were immunized at weeks 0 and 2 after 
sedation induced by injection of 150 µl 5% chloral hydrate in PBS. 
Serum samples were collected after 0–5 weeks.
All mice were purchased from Beijing Vital River Laboratory 
Animal Technology Co., Ltd. (the joint venture of Charles River 
Laboratories in China). This study was carried out in accordance 
with the recommendations of the Institutional Animal Care and 
Use Committee at the Sun Yat-Sen University Cancer Center. The 
protocol was approved by the Institutional Animal Care and Use 
Committee at the Sun Yat-Sen University Cancer Center, and 
the animals were cared for in accordance with the institutional 
guidelines.
enzyme-linked immunosorbent assay 
(elisa)
For determination of serum titers, 96-well ELISA plates (Corning) 
were coated with soluble gp350-ECD123-6His (100 ng in 100 µl PBS 
per well) at 37°C for 2 h. After one wash, the plates were blocked 
using 1× ED buffer (0.5% casein sodium salt, 2% gelatin, 0.1% pro-
clin-300, dissolved in 1× PBS) at 4°C overnight. Six 5-fold serial 
dilutions of serum samples were loaded on the plates (starting 
with dilution 1/100), and incubated for 1 h at 37°C, then washed 
with wash buffer. Secondary anti-mouse antibody conjugated with 
HRP (Promega) was diluted 1/20,000 and incubated for 45 min 
at 37°C. The signals were developed using EL-TMB kit (Sangon 
Biotech). Absorbance values at 450  nm were recorded, and the 
cutoff determined by OD values of pre-sera which was subtracted 
from experimental groups was set to 0.1. To determine the titers 
of gp350-specific Ig isotypes, the procedure was performed as 
before (46). Briefly, ELISA plates were coated with gp350-ECD123 
as described earlier and incubated with diluted sera samples. Then, 
the Ig isotypes were detected using HRP-conjugated goat anti-
mouse IgG1, IgG2a, IgG2b, IgG3, and IgA (1/10,000, Promega).
For competitive ELISA, mAb72A1 was directly conjugated 
with HRP using the HRP labeling kit (Proteintech). To quantify 
binding with mAb72A1-HRP, twofold serial dilution (starting 
at 1/100) were loaded on the plates coated with soluble gp350-
ECD123-6His. The antibody dilution yielding an absorbance of 
1.0 (i.e., 1/25,600) was chosen for competition tests. For com-
petition, twofold serial dilutions of serum samples (starting at 
1/50) were loaded on antigen-coated ELISA plates and incubated 
at 37°C for 1  h. Then, mAb72A1-HRP (dilution 1/25,600) was 
loaded on the plate and incubated at 37°C for 30 min, followed 
by signal development using the EL-TMB kit (Sangon Biotech). 
The  competitive ability of serum samples against mAb72A1 
was calculated using this equation: Percent of Inhibition 
% = [OD(−serum samples/+72A1) − OD(+serum samples/+72A1)]/OD(−serum samples/+72A1).
To characterize the binding of mAb72A1 to various gp350 
fusion proteins, the fusion proteins were coated on the ELISA 
plates as described earlier. 24 twofold dilutions of mAb72A1-HRP 
were added and incubated with gp350 fusion proteins at 37°C for 
45 min developed using EL-TMB kit.
To detect the binding with MBP-hCR2 SCR1-2, ELISA was 
performed as previously reported (45).
Determination of Molecular Weight Using 
analytical Ultracentrifugation (aUc) 
analysis
Sedimentation velocity experiments were used to determine 
the S value and molecular weight of the purified recombinant 
protein samples at 20°C on a Beckman XL-A analytical ultracen-
trifuge equipped with absorbance optics and an An60-Ti rotor. 
The samples were diluted to 1 OD at 280 nm. PBS was used as the 
reference buffer. The rotor speed was set at 35,000 rpm for these 
samples. The sedimentation coefficient was obtained using the 
c(s) method with the Sedfit software, which was kindly provided 
by Dr. P. Schuck at the National Institutes of Health (http://www.
analyticalultracentrifugation.com). And the molecular weight 
was calculated using the c(M) module of the Sedfit software.
surface Plasmon resonance (sPr)
Surface plasmon resonance-based antibody competition was 
conducted on a Biacore T200 instrument (GE Healthcare) as 
described previously (32). Briefly, soluble gp350-ECD123-6His was 
immobilized on the CM5 sensor chip (GE Healthcare) by amine 
coupling at pH 5.5 until the response unit (RU) value reached 
~500. Then, 50 µl of the serum samples (1/40 dilution) was injected 
at 30 µl/min, and the RU values were recorded as RU of serum. 
The chip was regenerated by one injection (50 µl) of 3 M MgCl2. 
Then, 50 µl (100 µg/ml) of mAb72A1 was injected at 30 µl/min 
before injecting of serum samples, and subsequently, the chip 
was regenerated by MgCl2. The RU values were documented as 
RU of mAb72A1. Competitive binding ability of serum samples 
to gp350 was calculated by an equation: Competitive percent-
age% = (RU of sera − RU of mAb72A1)/RU of sera.
For affinity kinetics analysis between recombinant gp350 and 
mAb72A1 or MBP-hCR2 SCR1-2, the three recombinant gp350s 
were immobilized on the CM5 sensor chip (GE Healthcare) at 
pH 5.5 with low RU value to avoid avidity effect. Then, mAb72A1 
or MBP-hCR2 SCR1-2 was injected at 30 µl/min, and the chip 
was regenerated by 10 mM glycine–HCl, pH 1.5. Surface bound-
kinetics fit (1:1 fit) was applied for data analysis, and χ2 less than 
10% of Rmax value was considered good.
infection Blocking assay
To test the sera’s ability to block EBV infection of B-lymphocytes, 
an infection blocking assay was performed according to previous 
reports (24). Briefly, EBVGFP was prepared using virus producing 
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cell line, CNE2-EBVGFP carrying Akata-EBV-GFP, and aliquoted 
100 µl per tube. Immunized sera or mAb72A1 were mixed gently 
with 100 µl EBV in 1.5 ml Eppendorf tube and incubated for 1 h 
at room temperature. Then, ~1 × 105 Akata negative cells (without 
latent EBV) were suspended with the mixture of antibodies and 
virus and incubated for 3 h at 37°C. Following the incubation, 
the cells were pelleted by centrifugation and washed once using 
1 ml PBS. Then, cells were grown in 1 ml RPMI1640 plus 10% 
FBS in 12-well plates for 2 days. Uninfected cells incubated with 
RPMI1640 media were used as negative controls, and cells incu-
bated with EBV, in the absence of immune serum, were included 
as positive controls.
After 2 days, the cells were collected and washed once with 
PBS. The EBV infection rate was determined using FACS analysis.
statistics
All statistical analyses were conducted with GraphPad Prism 
version 5. p-Values were generated by one-way ANOVA unless 
specified otherwise. p-Values of ≤0.05 were considered statisti-
cally significant.
resUlTs
construction and Production of secreted 
Fc Fusion Proteins
The fusion with Fc domain of immunoglobulin (IgG) has 
been shown to dramatically enhance the immunogenicity of 
antigens due to dimerization and high affinity for FcRn (37, 47). 
To enhance the immunogenicity and protection potential of 
EBV gp350, we generated two new Fc-based constructs. The first 
construct contains the gp350-ECD123 domains with the mIgG2a-
Fc domain at its C-terminus. These two domains are separated 
by a (Gly4Ser)3 linker to ensure correct protein folding and 
function (Figure  1A). Since the immunogenicity of the full-
length ectodomain of gp350 in the context of a fusion protein 
is not well characterized, we designed an Fc-based construct 
with gp350-ECDFL. The gp64 signal peptide was introduced at 
the N-terminus for protein secretion, and a Kozak sequence 
(GCCACC) was included to enhance transcription. For purifi-
cation of soluble gp350-ECD123, a 6× His tag was added at the 
C-terminus (Figure 1A).
For baculovirus production, Sf9 cells were transfected with 
recombinant bacmids for each construct. The fusion proteins were 
secreted into culture medium, and detected by Western blot and 
dot blot. For soluble gp350-ECD123, detection with an anti-His 
antibody yielded a single band of ~70 kDa under either reducing 
or non-reducing conditions by Western blot (Figure  1B). This 
is consistent with gp350-ECD123 being a monomer. For gp350-
ECD123-FcmIgG2a, Fc-detection yielded a ~110  kDa band under 
reducing condition and a ~220 kDa band under non-reducing con-
dition. This confirms the dimeric form of gp350-ECD123-FcmIgG2a. 
For gp350-ECDFL-FcmIgG2a, the apparent molecular weight under 
reducing conditions was ~200 kDa, and increased to ~450 kDa 
without reducing reagent. Under non-reducing conditions, 
smaller products are visible for gp350-ECDFL, which may indi-
cate Fc-containing fragments resulting from partial degradation 
of the fusion protein. In dot blot, the conformation-dependent 
neutralizing anti-gp350 monoclonal antibody mAb72A1 
specifically recognized all constructs, indicated that the functional 
region folded correctly (Figure 1C). To purify these fusion pro-
teins, affinity chromatography and gel filtration were performed 
(Figure  1D). We obtained homogenous preparations for each 
recombinant protein with molecular weights in agreement with 
the calculated values (data not shown). Fusion proteins containing 
gp350-ECD123 were well purified while gp350-ECDFL-Fc showed 
faint unrelated proteins, which were not detected by Western blot 
(not shown). Overall, the protein analysis shows that the gp350 
domains dimerized through Fc domain and were correctly folded 
and processed through the secretory pathway.
Binding of Fc Fusion Proteins With nab, 
mab72a1
To assess the proper activity of the recombinant gp350 fusion 
proteins, we tested their binding to the CR2/CD21 receptor and 
their recognition by the nAb mAb72A1. CR2/CD21 as acts as a 
receptor for gp350 to mediate entry of EBV into B-lymphocytes 
(25, 26). mAb72A1 is a specific nAb against gp350, which blocks 
EBV infection of B-lymphocytes through binding to the gp350 
region recognizing CR2/CD21. We used ELISA and SPR to 
characterize the affinity and binding kinetics between gp350 
and CR2/CD21 or mAb72A1. Purified MBP-hCR2 SCR1-2 was 
obtained from BL21 bacteria (see Materials and Methods), and 
mAb72A1 was purified from culture supernatants of HB168 
hybridoma cells (24).
By ELISA, the neutralizing mAb 72A1 appears to detect 
all constructs equally well (Figure  2A). However, the refined 
binding kinetics analysis by SPR shows that the affinity for the 
dimeric gp350-ED123-Fc increased by about 100-fold compared 
with the monomeric gp350-ECD123 (Table 1). Both the gp350-
ECDFL-Fc and gpECD123-Fc fusion proteins have the same affinity 
for the antibody (Table 1). Receptor binding was enhanced by 
fusing gp350-ECD123 to Fc. By ELISA, the dimeric constructs 
bound more soluble receptor than the monomeric gp350-ECD123 
(Figure  2B), but this may reflect a stoichiometric effect rather 
than an affinity effect. SPR kinetic analysis shows that the affinity 
of the receptor for the dimeric gp350-ECD123-Fc increased by 
about threefold compared with the monomeric gp350-ECD123 
(Table 1). The affinity of the full ectodomain Fc fusion protein 
for the receptors is somewhat similar to that of gp350-ECD123-Fc 
(Table 1). Overall, the KD values of Fc fusion proteins were mark-
edly smaller than that of the non-Fc fusion protein. This predicted 
higher affinity of Fc fusion proteins for the nAb mAb72A1 and 
for the receptor hCR2 likely results from the dimerization of Fc 
fragment.
To confirm the dimeric conformation of gp350 fusion pro-
teins caused by the Fc domain, the molecular weights of gp350 
fusion proteins were determined using AUC analysis. As shown 
in Figure 2C, the molecular weight of gp350-ECD123-6His was 
70.35  kDa, and that of gp350-ECD123-FcmIgG2a was 180.34  kDa, 
respectively. Thus, the Fc constructs have molecular weights cor-
responding to twice the size of the monomer and correspond to 
predicted values.
FigUre 2 | Molecular weight determination and binding kinetics analysis for recombinant gp350. (a) Binding of the indicated forms of recombinant gp350 to 
conformation-dependent neutralizing monoclonal antibody mAb72A1 by enzyme-linked immunosorbent assay (ELISA). BSA was included as negative control. (B) Binding 
of the indicated forms of recombinant gp350 to purified receptor MBP-hCR2 SCR1-2 by ELISA. Binding was normalized to maximum binding to monomeric gp350-
ECD123-6His. BSA was included as negative control. The Fc fusion proteins bound CR2 more effectively than the monomeric gp350. (c) Analytical ultracentrifugation 
determination of molecular weight of the indicated forms of recombinant gp350 after purification. Sedimentation coefficients and molecular weights are indicated.
TaBle 1 | Affinity and binding kinetics of recombinant gp350 with mAb72A1 
neutralizing antibody and hCR2 SCR1-2 receptor determined by surface 
plasmon resonance.
KD (M) ka (1/M s) kd (1/s) χ2
mab72a1
gp350-ECD123-6His 1.525 × 10−8 5.254 × 104 8.014 × 10−4 0.465
gp350-ECD123-FcmIgG2a 1.324 × 10−10 6.904 × 105 9.141 × 10−5 2.040
gp350-ECDFL-FcmIgG2a 1.819 × 10−10 5.817 × 105 1.058 × 10−4 2.490
hcr2 scr1-2
gp350-ECD123-6His 2.942 × 10−7 4.783 × 103 1.407 × 10−3 0.560
gp350-ECD123-FcmIgG2a 9.463 × 10−8 4.053 × 104 3.835 × 10−3 0.610
gp350-ECDFL-FcmIgG2a 6.847 × 10−8 1.755 × 104 1.201 × 10−3 0.839
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or monomeric gp350. Mice were injected and boosted i.p. with 
each antigen in the presence of Imject Alum adjuvant according 
to the schedule in Figure 3A. The specific anti-gp350 antibody 
titers were tested by ELISA against the monomeric gp350-ECD123. 
Serum titers from mice immunized with either gp350-Fc fusion 
protein were very significantly (p  <  0.001) higher than that of 
the control group immunized with monomeric gp350 for both 1 
and 20 µg doses (Figure 3B). The difference between monomeric 
and Fc-based gp350 antigen increased after a single boost for 
both doses tested. Considering that Fc fusion antigens could 
elicit an antibody response after mucosal immunization, we also 
immunized and boosted mice intranasally (i.n.) in the presence of 
CpG1826. Mice were boosted 2 weeks after the primary injection, 
and specific antibody titer against gp350 was determined 3 weeks 
later using ELISA (Figure 3A). As shown in Figure 3C, the serum 
titers of mice immunized i.n. with gp350-Fc fusion antigens were 
drastically higher than titers of mice immunized with monomeric 
gp350, which were similar to background signal likely due to 
non-specific serum IgG. After i.p. or i.n. injection, antibody titers 
in sera of mice immunized with gp350-ECDFL-FcmIgG2a appeared 
Fc Fusion antigen Were notably More 
immunogenic Than Monomeric gp350-
ecD123-6his in the Presence of alum 
or cpg adjuvants
To determine the immunogenicity of Fc fusion proteins in vivo, 
BALB/c mice were immunized with gp350-Fc fusion proteins 
FigUre 3 | gp350 proteins fused with FcmIgG2a domain were notably more immunogenic than monomers in the presence of adjuvants. (a) Diagram of the 
immunization protocols. Mice were boosted on week 2 for i.n. group or week 3 for i.p. group. (B) Mice (five per group) were immunized i.p. with 1 µg (left panel) or 
20 µg (right panel) recombinant proteins in Imject Alum adjuvant. (c) Mice (five per group) were immunized i.n. with PBS or recombinant gp350 proteins mixed with 
CpG1826. Black arrowheads indicate the times of boosts. Each data point represents mean ± SEM (n = 5). Significance (*p ≤ 0.05, **p < 0.01, and ***p < 0.001) 
between Fc fusion proteins versus monomer gp350 proteins is shown.
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slightly, but not significantly, lower than titers in sera of mice 
immunized with gp350-ECD123-FcmIgG2a. Overall, regardless of 
the immunization route, Fc-based gp350 antigens were more 
immunogenic than the native monomeric gp350.
immunization With Fc Fusion antigens 
Potently induced Production of nabs
To address the presence of nAbs in sera of gp350 immunized 
mice, competition ELISA and SPR were carried out against the 
neutralizing mAb72A1. This competition approach demonstrates 
the presence of antibodies in serum, which share overlapping 
epitopes with known strong neutralizing monoclonal antibod-
ies. This approach was validated for herpes simplex virus entry 
glycoproteins, where the ability of serum Ig to compete with 
specific nAbs directly correlated with the neutralizing ability 
of serum samples from infected and vaccinated individuals 
(48, 49). Wilson and Morgan showed a direct correlation between 
mAb72A1 competition and ability of mouse sera to neutralize 
infection (50). In the present competition ELISA, sera from mice 
immunized with gp350-Fc inhibited the binding of the neutral-
izing monoclonal antibody mAb72A1 to gp350 significantly 
better than sera from mice immunized with monomeric gp350 
(Figures  4A,B). At low serum dilution, more than 80% of the 
binding of the nAb could be blocked by sera from mice, which 
received the gp350-Fc antigens. It did not escape us that sera from 
mice mock-immunized with PBS have high competition effect in 
this setting (Figure 4B). We decided to show the complete data 
rather than subtracting this background. Similar effect was seen 
previously in competition experiments (47). This indicates that 
i.n. immunization with monomeric gp350-ECD123 leads to low or 
no production of nAbs similar to mAb721A1.
The competition percentage was also evaluated by SPR for 
i.p. and i.n. immunizations (Figure 4C). Here, the competitive 
percentage represents the% reduction of serum Ig binding to 
gp350 following binding of the potent neutralizing mAb72A1. 
mAb72A1 reduced the gp350 binding ability of seric Ig from mice 
immunized i.p. with gp350-ECD123-Fc and gp350-ECDFL-FC by 
12 and 8%, respectively. When i.n. immunization was performed, 
the competitive percentages were 8 and 6% for the respective 
dimeric antigens. By contrast, binding of serum Ig from mice 
immunized with the monomeric gp350-ECD123-6His was not 
affected by the neutralizing monoclonal antibody. These competi-
tion data show that the sera from mice immunized with gp350-Fc 
antigens, but not with monomeric gp350, contained antibodies 
that detect the neutralizing epitope specified by mAb72A1.
FigUre 4 | Immunization with Fc-based recombinant gp350 proteins elicits dramatically higher neutralizing titers than monomers. (a) Competition enzyme-linked 
immunosorbent assay (ELISA). BALB/c mice (five per group) were immunized i.p. with 1 µg (left panel) or 20 µg (right panel) of the indicated proteins in Alum 
adjuvant. Serum dilutions were used to block binding of neutralizing monoclonal antibody mAb72A1 to monomeric gp350 in competition ELISA. Percentage of 
inhibition of mAb72A1 binding is reported. (B) Competition ELISA. BALB/c mice (five per group) were immunized i.n. with 20 µg proteins assisted by CpG. Sera were 
analyzed for the ability to block mAb72A1 as in panel (a). Each data point represents mean ± SEM (n = 5). (c) Competition by surface plasmon resonance (SPR). 
Neutralizing mAb72A1 was used to compete binding of serum immunoglobulin from mouse immunized with the indicated antigens to immobilized monomeric gp350 
by SPR. The percentage of reduction of serum Ig binding is indicated. Each symbol represents the serum of one mouse (five mice per group), and the bars show 
mean ± SEM values. Significance (*p ≤ 0.05, **p < 0.01, and ***p < 0.001) between Fc fusion proteins versus monomer gp350 proteins is shown.
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To determine whether the nAbs detected by competitive 
ELISA and SPR in Fc-350 sera have anti-EBV activity, the ability 
of these sera to block EBV infection of B-lymphocytes was tested. 
In this neutralization assay, EBVGFP produced from CNE2 cells 
was incubated with diluted sera, and used to infect Akata cells 
(EBV negative). The neutralizing monoclonal mAb72A1 was 
included as a positive control.
Figure 5A shows the results for sera from mice immunized 
i.p. with 20  μg of the indicated antigens when diluted 10× or 
40×. As expected, preimmune serum added only a limited 
effect compared with the negative control. Globally, immuniza-
tion with the monomeric gp350-ECD123-6His did not elicit 
significant protection, although a couple of sera had more 
noticeable neutralizing effect compared with preimmune serum. 
By contrast, sera from mice immunized with either gp350-Fc 
construct, blocked infection efficiently at both dilutions (10× 
and 40×). The Fc-based constructs were significantly more 
potent than monomeric gp350 at both dilutions. The results 
of EBV neutralization assay with sera of mice that received a 
lower dose of antigen (1 μg) follow a similar trend (Figure 5B). 
FigUre 5 | Neutralization of EBVGFP infection by sera collected at week 5 post-immunization. Recombinant EBVGFP was preincubated with 10× or 40× dilutions of 
sera from mice immunized with the indicated antigens. Virus was added to Akata cells, and GFP fluorescence was recorded as a measure of infection. The reported 
infection rates consist in the percentages of GFP positive cells as analyzed by flow cytometry. Virus infection was blocked by diluted sera developed through 
immunization. (a) Mice immunized i.p. with 1 µg antigen. (B) Mice immunized i.p. with 20 µg antigen. (c) Mice immunized i.n. with 20 µg antigen. Significance 
(*p ≤ 0.05, **p < 0.01, and ***p < 0.001) between Fc fusion proteins versus monomer gp350 proteins is shown.
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However, the absolute neutralization potential was diminished, 
especially for the gp350-ECDFL-Fc, which was not significantly 
better than monomeric gp350. Sera from mice immunized with 
gp350-ECD123-Fc were only significantly protective when diluted 
10-fold. At 40× dilution, it was limited to some but not all mice 
in each immunized group.
FigUre 6 | Specific titers of anti-gp350 IgG isotypes and IgA in sera are markedly elevated post-immunization with Fc-based gp350 proteins. (a–D) Titers of 
gp350-specific IgG subtypes were determined in sera (5 weeks post-immunization) of mice immunized i.p. or i.n. with 20 µg of the indicated antigen. (e) Anti-gp350 
IgA serum titers from mice immunized i.n. with 20 µg of the indicated antigens. Each symbol represents an individual serum. Horizontal bars represent mean values. 
Significance (*p ≤ 0.05, **p < 0.01, and ***p < 0.001) between Fc fusion proteins versus monomer gp350 proteins is shown.
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After intranasal immunization with 20 μg of antigen, gp350-
ECD123-Fc, provided 100% neutralization with 10× diluted serum 
(Figure 5C). It was more efficient than gp350-ECDFL-Fc, but both 
Fc constructs were significantly better than monomeric gp350-
ECD123-6His at both dilutions of sera.
We also tested whether there was a direct correlation between 
total anti-gp350 titers and ability of sera from different groups to 
block EBV infection of B cells. We found a strong linear correlation 
between total anti-gp350 titers (5 weeks post-immunization) and 
neutralizing activity (Figure S1 and Table S1 in Supplementary 
Material). The same correlation was observed at different dilution 
of sera (10×, 40×) used in these assays. The linear correlation 
occurred across all three forms of antigens for each route of 
immunization. Thus, Fc-based dimerization increased total titers 
and neutralizing titers in a similar manner. Overall, these data 
indicate that the immunogenicity of gp350-ECD123 was notably 
enhanced by fusion with an Fc domain.
immunization With gp350-ecD123-Fcmigg2a 
elicited Markedly higher Titers of igg 
isotypes and iga
We compared the titers of different IgG isotypes between mice 
immunized with the various gp350 antigens (Figure  6). This 
analysis confirms that gp350-Fc is more immunogenic than 
monomeric gp350. The Fc-based antigens elicited more IgG1 and 
IgG2b than the monomeric counterpart gp350-ECD123-6His after 
i.p. immunization (Figures  6A,C). And after i.n. immunization, 
the gp350-Fc antigens induced markedly more IgG1, IgG2a, and 
IgG2b. Interestingly, all gp350 antigens elicited the same titer of 
IgG3, mostly after i.p. immunization (Figure 6D). The IgA serum 
titer was tested for mice immunized intranasally (Figure 6E). The 
specific IgA titers elicited by the immunization with Fc fusion 
proteins increased to some extent and follow the same trend as the 
IgG subtypes, although there is no statistical variation in this case. 
Enhancing the mucosal immunogenicity of gp350-Fc antigens may 
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be improved by using adjuvants that are better adapted than CpG 
to elicit mucosal immunity [e.g., Poly(I:C), PEI]. Overall, these data 
confirm the highest immunogenicity of the Fc-based construct 
gp350-ECD123-Fc.
DiscUssiOn
In our systematic study of the immunogenicity of the EBV enve-
lope gp350 antigen, the full-length ectodomain (gp350-ECDFL) 
or functional domains 1-2-3 of the glycoprotein (gp350-ECD123) 
were fused to the Fc domain of mouse IgG2a. We showed that the 
Fc portion led to the dimerization of the normally monomeric 
gp350. Fusion with the Fc domain did not affect the native con-
formations of the receptor-binding domain and putative neutral-
izing epitopes. Indeed, the recombinant antigens with or without 
Fc domains have similar binding affinity and kinetics for the 
potent nAb, mAb72A1, and for the receptor, hCR2/CD21. More 
importantly, immunization with Fc-based gp350 fusion antigens 
elicited markedly more potent protection against EBV infection 
of B  cells compared with monomeric gp350. This enhanced 
protection correlates with higher titers of nAbs in sera of mice 
immunized with the Fc-based gp350 constructs. When compar-
ing both Fc-based constructs, it is not clear why gp350-ECD123-Fc 
was a more potent immunogen compared with the full ectodo-
main gp350-ECDFL-Fc. It may be because it contains fewer non-
neutralizing epitopes compared with the full-length ectodomain. 
Alternatively, it may be caused by eliciting different Ig isotypes, 
although the contribution of each isotype to neutralization has 
not been determined. Finally, gp350-ECD123-Fc may be a more 
stable antigen with less degradation than gp350-ECDFL-Fc. In all 
our assays, we also observed a direct correlation between total 
anti-gp350 titers and inhibition of infection of B-cells (Figure 
S1 and Table S1 in Supplementary Material). This finding across 
three different forms of the gp350 antigens supports previous 
observations that anti-gp350 titers correlate better with inhibi-
tion of B-cell infection than anti-gp42 titers in humans (51).
The immunogenicity of monomer antigens is frequently 
enhanced through multimerization (52–55). In recent years, 
research on the development of EBV prophylactic vaccines has 
focused on the use of multimerization elements to improve 
immunogenicity. Cui et  al. reported that a tetrameric gp350 
linked by a leucine zipper domain and a trimer of gH/gL linked 
by the T4 fibritin foldon elicited more potent antigen-specific 
IgG and cytokine responses (56, 57). Kanekiyo et al. tested the 
immunogenicity of ferritin-based gp350 vaccine candidates in 
mice and non-human primates (32). Their results suggested 
that this approach induced potent nAbs. In the absence of 
direct comparison, one can only speculate about the most 
effective way of presenting gp350 as a dimer or a multimer. The 
Fc fusion approach has the advantage of having been validated 
in other human clinical trials (37, 43). Also, gH/gL-EBNA1 and 
gB-LMP2 fusion proteins have been showed to induce high 
antibody titers and EBV-specific T-cell responses in mice (58). 
Moreover, when fused with KLH, peptides, which have high 
affinity to EBV host cells, led to the production of neutralizing 
monoclonal antibodies against EBV (59, 60). Multimerization 
elements have shown many application prospects in these 
studies. However, the clinical safety and durability of these 
different approaches need further investigation, if possible in 
direct comparison, to be considered for clinical use.
The safety of Fc fusion protein as drugs has been widely vali-
dated in numerous clinical trials (37, 43). The Fc domain endows 
the recombinant antigens with a slower renal clearance rate due to 
dimerization and increased molecular weight. Through interaction 
with its corresponding receptor, FcRn, the plasma half-life of Fc 
fusion antigens was remarkably increased (37, 40, 42). Furthermore, 
the dimerization through Fc may induce a more efficient B  cell 
receptor cross-linking (57). Based on the advantages brought by 
fusion with the Ig Fc domain, the immunity of antigens was potently 
enhanced (61). Besides, the antigens attached to Fc domain could 
be presented to APCs to elicit mucosal immunity. Altogether, the 
Fc-based version of an antigen is considered superior to its wild-type 
monomeric counterpart in preventing diseases acquired through 
mucosae (47, 62). EBV, which was described as one “kiss” virus, 
initiates infection of the host by infecting mucous epithelial cells 
(63). Consequently, this Fc-based approach serves as a new template 
to develop EBV prophylactic vaccine that target the initial infection 
of mucosa. Our data support the benefit of fusion of gp350 with 
the IgG Fc domain which has been preferred in vaccine design (i.e., 
mouse IgG2a or human IgG1). However, Fc domains from other 
Ig subtypes such as IgE and IgM, which have various affinities for 
different receptors, could be envisaged in further studies (37). For 
tests in non-human primates and for clinical use, human IgG1 Fc is 
preferred. The ability of hIGg1 to enhance immunogenicity of EBV 
gp350 is expected to be similar to that of the constructs based on 
mIgG2a presented here. Characterization of human Fc-based gp350 
antigens is ongoing.
Previous gp350-based multimeric antigens have been tested in 
mouse models, including tetrameric gp350, virus-like particles, 
and ferritin nanoparticles (32, 57, 64). Due to different readout 
assays and protocols of injections, and because doses cannot be 
directly compared, any quantitative comparisons of total and 
neutralizing titers have to be interpreted very carefully. All these 
studies compare multimeric gp350 to a monomeric antigen, as we 
did here. This provides a framework to normalize and compare 
the efficacy of each approach. We found that Fc-based dimeriza-
tion increased titers by 10- to 100-fold over monomeric gp350 
(Figures  3B,C). This is in the range of titer increase reported 
for other multimeric forms of gp350 (32, 57,  64). Addition of 
Fc domains increased neutralization efficacy by about 100-fold 
(Figure 5). By comparison, the Fc-based approaches (20 µg i.n. 
or i.p.) appear as efficient ways of increasing anti-gp350 neutrali-
zation titers. Clearly, a side-by-side comparison with matched 
doses and analyses is needed to directly identify the most prom-
ising vaccine candidates in terms of efficacy and safety.
In previous clinical attempts, prophylactic vaccines targeting 
gp350 failed to block EBV infection in humans despite their 
ability to induce neutralizing Abs in rodent or non-human 
primates (17). In our study, when BALB/c mice were immunized 
with similar soluble gp350 monomers, only a few sera could 
block EBV infection of B-lymphocytes in vitro. By comparison, 
immunization with Fc-based recombinant gp350 increased neu-
tralization titers and protection ability in vitro. This suggests that 
Fc-based gp350 antigens could provide a more potent protection 
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against EBV infection, which may be due to the interaction of 
the Fc domain with its corresponding receptors. Furthermore, 
considering the complexity of the EBV virion envelope, a com-
bination of gp350-Fc with other glycoproteins antigens could be 
included in candidate vaccine formulations. This may provide 
broader protection against EBV, which uses different subsets 
of glycoproteins to infect lymphocytes and epithelial cells. For 
instance, the potential application of gH/gL heterodimer and gB 
(a natural trimer) in EBV vaccine preparation has been discussed 
in previous reports since these essential glycoproteins are targeted 
by nAbs (56). However, very little information is available about 
the rational molecular design and optimal adjuvant formulation. 
Though some efforts have been made to investigate the usage 
of EBV gH/gL dimer and gB in vaccine research, it remains to 
be determined whether such antibodies would cut off the EBV 
infection in non-human primates.
In conclusion, our data with EBV gp350 suggest that the 
rational design to fuse the IgG Fc domain with the ectodomains 
of EBV glycoproteins could enhance immunogenicity, thereby 
providing more marked and universal protection against EBV 
infection. This strategy will guide further investigation to design 
EBV prophylactic vaccine, such as combinations of several EBV 
surface glycoproteins.
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